MeSH D015266 - merkel cell carcinoma
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| EMD Serono | Avelumab | Bavencio |  | 2017-03-23 |  |  |
| Incyte | Retifanlimab | Zynyz |  | 2023-03-22 | $1.91 M | Q3/23-Q3/24 |
| Merck & Co | Avelumab | Bavencio |  | 2017-09-18 |  |  |
Clinical Trials
Historical Success Rate
Phase 1
64%27/42
Phase 2
6%2/35
Phase 3
67%2/3
Approved: 1Overall Success rate: 2%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use